The mutational prevalence of TP53 was 3% in aggressive variants of PTC, which is considered a hallmark of advanced thyroid carcinoma; this value was higher than that of PTCs from TCGA (0.7%), but lower than that of advanced PTCs (10%), as well as PDTCs (8%) or ATCs (10%) from MSKCC data (Figure 2). Here, TP53 is linked to thyroid gland carcinoma.